来凯医药科技（上海）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Laekna Releases 2023 ESG Report 2024-04-29 20:30
Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024 2024-04-08 08:30
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024 2024-01-04 12:40
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results 2023-12-11 18:55
Laekna, Inc. (2105.HK) Announces Interim Results 2023 2023-08-25 08:00
Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102 2023-05-21 22:23
Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study 2022-09-06 17:02
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer 2022-05-26 20:27
Laekna Therapeutics Raises $61 Million in Series D financing 2022-05-18 20:00
Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board 2022-03-29 20:00
Laekna Launched the new domain name www.laekna.com 2022-02-07 12:47
Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase 2021-12-24 16:30
Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress 2021-09-16 17:06
Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer 2021-08-27 11:20
Laekna Therapeutics will present two clinical study results in ESMO 2021 2021-07-26 13:26
1